fabry disease
Showing 1 - 25 of 164
Fabry Disease Trial in Seoul (Fabagal® (Agalsidase beta), Active comparator (Agalsidase beta))
Recruiting
- Fabry Disease
- Fabagal® (Agalsidase beta)
- Active comparator (Agalsidase beta)
-
Seoul, Songpa-gu, Korea, Republic ofSeoul Asan Center
Oct 10, 2023
Adenine Phosphoribosyltransferase Deficiency, AH Amyloidosis, AHL Amyloidosis Trial in Bristol
Recruiting
- Adenine Phosphoribosyltransferase Deficiency
- +83 more
-
Bristol, South West, United KingdomZoe Plummer
Sep 26, 2023
Assess Urine Biomarkers to Predict Nephropathy in Fabry Disease
Recruiting
- Fabry Disease
-
Rockville, Maryland
- +1 more
Sep 29, 2023
Fabry Disease Trial in Taipei
Recruiting
- Fabry Disease
-
Taipei, TaiwanInvestigational Site Number :1580001
Sep 24, 2023
Autoimmune and Inflammatory Response Biomarkers in Fabry Disease
Recruiting
- Fabry Disease
-
Madrid, SpainHospital Universitario Ramón y Cajal
Aug 18, 2023
Fabry Disease Trial in Bron, Lyon (T1 mapping measurement)
Not yet recruiting
- Fabry Disease
- T1 mapping measurement
-
Bron, France
- +1 more
Jun 27, 2023
Fabry Disease Trial in Buenos Aires (Recombinant human alpha galactosidase A (agalsidase beta), Recombinant human
Recruiting
- Fabry Disease
- Recombinant human alpha galactosidase A (agalsidase beta)
- Recombinant human alpha-galactosidase A (agalsidase beta)
-
Buenos Aires, ArgentinaInstituto de Investigaciones Clínicas Quilmes
Apr 24, 2023
Fabry Disease Trial in Roma (Sample blood and 2D-echocardiography with Doppler)
Recruiting
- Fabry Disease
- Sample blood and 2D-echocardiography with Doppler
-
Roma, ItalyFondazione Policlinico Gemelli
Feb 27, 2023
Fabry Disease Trial (PRX-102 1 mg/kg every 2 weeks, PRX-102 2 mg/kg every 4 weeks)
Not yet recruiting
- Fabry Disease
- PRX-102 1 mg/kg every 2 weeks
- PRX-102 2 mg/kg every 4 weeks
- (no location specified)
Jan 24, 2023
Fabry Disease Trial (Dapagliflozin 10mg Tab, Placebo)
Not yet recruiting
- Fabry Disease
- Dapagliflozin 10mg Tab
- Placebo
- (no location specified)
Jan 23, 2023
Fabry Disease Trial in United Kingdom, United States (ST-920)
Recruiting
- Fabry Disease
- ST-920
-
Irvine, California
- +20 more
Feb 1, 2023
Cardiac Imaging Diagnostic Assay for Monitoring Fabry Disease
Not yet recruiting
- Fabry Disease
- Agalsidase beta
- (no location specified)
Jan 30, 2023
Fabry Disease Trial in Melbourne, Perth, Taipei (4D-310)
Active, not recruiting
- Fabry Disease
- 4D-310
-
Melbourne, Australia
- +2 more
Jan 30, 2023
Choices Through the Eyes of the Patients
Not yet recruiting
- Fabry Disease
- This is a non-interventional study
-
Eagan, MinnesotaEngage Health
Jan 30, 2023
Cardiovasculorenal Phenotyping in Fabry Disease Through
Not yet recruiting
- Fabry Disease
- Measures of arterial stiffness and endothelial function
- +3 more
- (no location specified)
Jan 24, 2023
Pain and Quality of Life of Patients With Fabry Disease
Recruiting
- Fabry Disease
-
Seoul, Korea, Republic ofDivision of Cardiology, Yonsei Cardiovascular Hospital, Yonsei U
Jan 18, 2023
Fabry Disease in Portuguese Idiopathic Cardiomyopathies
Recruiting
- Fabry Disease
- Alfa-galactosidase activity and genetic testing for Fabry diagnosis
-
Porto, PortugalCentro Hospitalar Universitário São João
Jan 12, 2023
Fabry Disease Trial in Worldwide (migalastat HCl 150 mg)
Recruiting
- Fabry Disease
- migalastat HCl 150 mg
-
Atlanta, Georgia
- +8 more
Jan 11, 2023
Based on Electronic Health RecOrds to Identify Patients at
Not yet recruiting
- Fabry Disease
- (no location specified)
Dec 20, 2022
Fabry Disease Trial in India (Replagal)
Recruiting
- Fabry Disease
- Replagal
-
Hyderabad, India
- +4 more
Nov 2, 2022
Both Patients and Their Clinicians in Treatment of Fabry Disease
Completed
- Fabry Disease
- Agalsidase Beta
- Agalsidase Alpha
-
Philadelphia, Pennsylvania
- +8 more
Oct 27, 2022
Fabry Disease Trial in United States (Pegunigalsidase Alfa)
Available
- Fabry Disease
- Pegunigalsidase Alfa
-
Birmingham, Alabama
- +10 more
Oct 20, 2022